General

Multiple myeloma: practice patterns across Europe. Raab MS et al. Br J Haematol. 2016 Jun 13. doi: 10.1111/bjh.14193. [Epub ahead of print]. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. Prasad V et al. Mayo Clin Proc. 2016 Jun;91(6):707-12. doi: 10.1016/j.mayocp.2016.04.028. Pomalidomide in the management of…

Supportive care

Citrate Extended High Cut-Off Hemodiafiltration for Renal Recovery in Patients With Multiple Myeloma. Marn Pernat A et al. Ther Apher Dial. 2016 Jun;20(3):251-5. doi: 10.1111/1744-9987.12432. Effective Removal of x03BA;-Free Light Chains with Hemodialysis Using Fresenius Ultraflux® EMiC®2 Dialyser in a Patient with Myeloma Cast Nephropathy, with Associated Cost Savings. Jayaballa M et al. Blood Purif. 2016 Jun 8;42(2):158-159. [Epub ahead of print]. Thirteen treatment…

Complications of myeloma and its treatments

Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs. Chalayer E et al. Am J Hematol. 2016 Jun 24. doi: 10.1002/ajh.24454. [Epub ahead of print]. Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation and severe graft versus host disease. Karrasch…

Current treatments

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. Hulin C et al.J Clin Oncol. 2016 Jun 20. pii: JCO667295. [Epub ahead of print]. A multicenter clinical study to determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following…

Diagnostic tests and prognostic indicators

Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. Terpos E et al. Blood Cancer J. 2016 May 27;6:e428. doi: 10.1038/bcj.2016.37. Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis. Bhatti S et al. Eur Heart J Cardiovasc Imaging. 2016 May 25. pii: jew101. [Epub…

Related conditions

The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients. Cao XX et al. Leuk Res. 2016 May 4;46:85-88. doi: 10.1016/j.leukres.2016.05.002. [Epub ahead of print]. Rare and unusual clinicopathologic presentation of renal AL amyloidosis. Logan A et al. JRSM Open. 2016 May 3;7(5):2054270416640156. doi: 10.1177/2054270416640156. eCollection 2016. Diagnosis, risk stratification and management of monoclonal gammopathy of…

Emerging treatments

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Moreau P et al.Drugs. 2016 May;76(8):853-67. doi: 10.1007/s40265-016-0573-4. Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Tandon N et al. Clin Pharmacol. 2016 May 6;8:35-44. doi: 10.2147/CPAA.S94021. eCollection 2016. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Usmani SZ et…

Biology and genetics

Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma. Song Y et al. Leukemia. 2016 May 20. doi: 10.1038/leu.2016.97. [Epub ahead of print]. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Krejcik J et al. Blood. 2016 May 24. pii: blood-2015-12-687749. [Epub ahead of print]. Unusual cytological features in multiple myeloma. Abdulsalam AH et al. Am J Hematol. 2016 May 24.…

General

NCCN Guidelines Update for Multiple Myeloma. Anderson KC. J Natl Compr Canc Netw. 2016 May;14(5 Suppl):675-7. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Sobh M et al. Leukemia. 2016 May 20. doi: 10.1038/leu.2016.101. [Epub ahead of print]. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in…

Supportive care

Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice? Chalayer E et al.Thromb Res. 2016 May 7;143:101-102. doi: 10.1016/j.thromres.2016.05.003. [Epub ahead of print]. Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study. Gerth HU et al. PLoS One. 2016 May 6;11(5):e0154993. doi: 10.1371/journal.pone.0154993. eCollection…